PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30597306-5	2019	Moreover, AGD significantly inhibited LPS/GalN-induced inflammatory responses in mice with ALI by reducing not only the secretion of tumour necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6 but also the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2).	Galactosamine	42-46	interleukin 1 beta	Mus musculus	169-191	
26325539-9	2016	Cultured hepatic macrophages from GalN/LPS-treated knockout mice had similarly increased IL-1beta production.	Galactosamine	34-38	interleukin 1 beta	Mus musculus	89-97	
28125915-6	2018	Furthermore, GalN/LPS increased nuclear factor kappa-B activation and the levels of tumor necrosis factor-alpha and interleukin-1beta.	Galactosamine	13-17	interleukin 1 beta	Mus musculus	116-133	
11093734-2	2000	Pretreatment with TNF-alpha or interleukin-1beta (IL-1beta), which activated NF-kappaB in the liver, dramatically prevented TNF-alpha-induced liver-cell apoptosis in D-galactosamine (GalN)-sensitized mice, but not anti-Fas antibody-induced hepatotoxicity.	Galactosamine	166-181	interleukin 1 beta	Mus musculus	31-48	
21928088-11	2012	The expression of TNF-alpha and interleukin (IL)-1beta were increased in the GalN/LPS group.	Galactosamine	77-81	interleukin 1 beta	Mus musculus	32-54	
23994575-9	2013	Serum levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-1beta increased after GalN/LPS treatment; these increases were attenuated by hemin.	Galactosamine	99-103	interleukin 1 beta	Mus musculus	60-82	
23994575-10	2013	Hepatic mRNA levels of TNF-alpha, IL-1beta, and NLRP3 increased after GalN/LPS treatment, and hemin attenuated increases in TNF-alpha and IL-1beta.	Galactosamine	70-74	interleukin 1 beta	Mus musculus	34-42	
11093734-2	2000	Pretreatment with TNF-alpha or interleukin-1beta (IL-1beta), which activated NF-kappaB in the liver, dramatically prevented TNF-alpha-induced liver-cell apoptosis in D-galactosamine (GalN)-sensitized mice, but not anti-Fas antibody-induced hepatotoxicity.	Galactosamine	166-181	interleukin 1 beta	Mus musculus	50-58	
11093734-2	2000	Pretreatment with TNF-alpha or interleukin-1beta (IL-1beta), which activated NF-kappaB in the liver, dramatically prevented TNF-alpha-induced liver-cell apoptosis in D-galactosamine (GalN)-sensitized mice, but not anti-Fas antibody-induced hepatotoxicity.	Galactosamine	183-187	interleukin 1 beta	Mus musculus	31-48	
11093734-2	2000	Pretreatment with TNF-alpha or interleukin-1beta (IL-1beta), which activated NF-kappaB in the liver, dramatically prevented TNF-alpha-induced liver-cell apoptosis in D-galactosamine (GalN)-sensitized mice, but not anti-Fas antibody-induced hepatotoxicity.	Galactosamine	183-187	interleukin 1 beta	Mus musculus	50-58	
10464143-8	1999	Suppression of Fas-induced activation of the caspase by IL-1beta was diminished by coadministration with D-galactosamine and reversed by coinjection with an excess amount of uridine.	Galactosamine	105-120	interleukin 1 beta	Mus musculus	56-64	
1612727-4	1992	Inhibition was apparent in normal and D-galactosamine (GalN)-sensitized mice and occurred at the pretranslational level, as splenic TNF and interleukin-1 beta mRNAs were present in lower amounts in LPS-stimulated mice pretreated with Rs-DPLA.	Galactosamine	38-53	interleukin 1 beta	Mus musculus	140-158	
1612727-4	1992	Inhibition was apparent in normal and D-galactosamine (GalN)-sensitized mice and occurred at the pretranslational level, as splenic TNF and interleukin-1 beta mRNAs were present in lower amounts in LPS-stimulated mice pretreated with Rs-DPLA.	Galactosamine	55-59	interleukin 1 beta	Mus musculus	140-158